NCT00297947View on ClinicalTrials.gov

High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions
SchizophreniaSchizoaffective Disorder
Interventions
DRUG

quetiapine

Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.

DRUG

quetiapine

Participant will receive 600 mg/day of quetiapine for 8 weeks.

Trial Locations (2)

10035

Manhattan Psychiatric Center, New York

10962

Nathan Kline Institute for Psychiatric Research, Orangeburg

All Listed Sponsors
collaborator

Nathan Kline Institute for Psychiatric Research

OTHER

lead

Manhattan Psychiatric Center

OTHER

NCT00297947 - High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder | Biotech Hunter | Biotech Hunter